ArticleBMC infectious diseases2026
Use of anti-nucleocapsid antibody detection as a marker of SARS-CoV-2 infection in healthcare professionals: a longitudinal seroprevalence study at a university hospital in Catalonia, Spain.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundHealthcare workers (HCWs) are at increased risk of SARS-CoV-2 infection due to their continuous exposure during the COVID-19 pandemic. Serological detection of anti-nucleocapsid (anti-N) antibodies offers a valuable approach to estimate cumulative infection rates, including asymptomatic and undiagnosed cases missed by molecular testing.
methodsWe performed a longitudinal retrospective study involving HCWs at Althaia Xarxa Assistencial Universitària, Manresa (Spain), from June 2020 to November 2021. Participants underwent two rounds of serological testing with the Elecsys® Anti-SARS-CoV-2 assay (Roche) to quantify total anti-N antibodies. Concurrently, results from direct diagnostic tests (PCR or antigen detection) were collected. Seroprevalence, antibody concentrations, and infection rates—based on seroconversion and PCR/antigen positivity—were evaluated at both time points.
resultsOf the 758 HCWs included (84% female, median age 45 years), anti-N seroprevalence increased from 11.1% in June 2020 to 23.4% in November 2021. Median anti-N antibody levels declined significantly from 95.1 COI to 18.7 COI across the study period. The estimated infection rate between the two rounds was 12.1%. Serological testing identified a higher proportion of infections than direct diagnostic methods in the second period (23.4% vs. 17.9%). Three participants showed suspected reinfection, evidenced by rising antibody titers, and six participants seroreverted, all initially presenting low antibody levels.
conclusionsAnti-N serology effectively identifies past SARS-CoV-2 infections, particularly in asymptomatic HCWs undetected by PCR or antigen tests. Longitudinal monitoring reveals a marked decline in antibody concentrations over time. Incorporating anti-N serological testing alongside molecular diagnostics can enhance retrospective infection surveillance and aid in the detection of reinfection.
trial registrationThis study was retrospectively registered with the Institutional Ethics Committee of the Catalan Hospital Union (Unió Catalana d’Hospitals), reference number 40/21, on June 7, 2021.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.